Navigating Patent Linkage, Generic Drugs & Regulatory Approval

In the ever-evolving and ever-competitive pharmaceutical landscape, the interplay between patent linkage, generic drug entry and regulatory approval processes has become a critical focal point. The pharmaceutical industry thrives due to the two main kinds of drugs such as original or innovator's drug and generic drugs. The original drug or innovator's drugs are manufactured as a result of extensive research and development and rigorous clinical trial phases. This complex pharma landscape necessitates a thorough understanding for the purpose of ensuring continued innovation in the marketplace which in turn ensures drug affordability to the public at large. India is known as the pharmacy of the world due to its ability to manufacture generic drugs at a large scale and export the same across the world. The generic drugs are known for its cost-effectiveness which is seen as cheaper alternatives with equal efficiency as that of an original drug. The patent linkage system advocates for linking the marketing approval of a drug with the validity of the patent.

The original drug manufacturer enjoys patent protection over the patented drug for a period of 20 years which is offered as an incentive for the r&d costs incurred by them. During the subsistence of the patent no third party other than the patent holder or any person authorised by such patent holder can manufacture, sell or reproduce the patented drug. However, after the expiration of the patent term the generic drug manufacturers can create the cheaper alternative thereby ensuring affordability and faster accessibility of the patented drugs to the public at large. These generic drugs are chemically identical to the original drugs particularly in terms of the active ingredients, strength, dosage and quality. In addition to this, the generic drugs in order to obtain marketing approval must be bio-equivalent to the original drug. Bio-equivalence herein refers to the therapeutic effect of the generic drugs.

The Patent linkage system is surrounded by both positive and negative arguments. On the positive note, this system offers better protection for the patent holders while the critics are of the view that this system increases drug costs and delays the entry of generic drugs into the market thereby in turn delaying accessibility.

Introduction

The patent linkage system lies at the heart of the pharmaceutical sector as it strikes a delicate balance between incentivizing innovation on one hand and facilitating generic drug competition and its market entry. The patent system aims to protect the new drug manufacturer's investments in research and development by enabling them to monopolise the drug through patent for a limited duration thereby aiding the original drug manufacturers to recoup the r&d costs. Once the patent term ends, the generic drug manufacturers are allowed to manufacture drugs with similar therapeutic efficiency by relying upon the NDA (New Drug Application of the original drugs) which is known as the abbreviated pathway for the generic drug manufacturers. The generic drug manufacturers in order to establish the generic drug's safety, efficacy and effectiveness can file ANDA (Abbreviated New Drug Application) in order to ensure the cost-effectiveness of the generic drugs which enables them to reduce the r&d costs and the time involved. However, navigating this complex terrain requires a deep comprehension of the intricate regulatory approval processes and their implications for both innovator companies and generic manufacturers.

Dissecting Patent Linkage

Patent linkage is a mechanism that links the marketing approval of a generic drug to the patent status or validity of the patent. This system primarily seeks to prevent the early entry of generic drugs into the market while the patent term still subsists. The system of patent linkage sparks controversy because the patent system in India is governed by the Patent Act, 1970 while on the other hand, the marketing approval of drugs is dealt under the Drugs and Cosmetics Act, 1940. The authorities dealing with both the systems are also independent and distinct as the Office of the Controller General of Patents, Designs and Trade Marks looks after the patent system while the drug regulatory approval takes place under the oversight of the Central Drugs Standard Control Organisation. The patent linkage system expects the drug regulatory authority to check the patent validity while granting marketing approval for drugs.

Navigating the Regulatory Landscape

The regulatory approval processes for both original and generic drugs are intricate and multifaceted. For original drugs, rigorous clinical trials and extensive data submissions (r&d) are required in order to establish safety, efficacy and efficiency of the drugs. The generic drug approvals largely depends upon the bioequivalence studies and abbreviated pathway.

Key regulatory considerations include:

New Drug Applications (NDAs) for branded drugs
Abbreviated New Drug Applications (ANDAs) for generic drugs
Risk Evaluation and Mitigation Strategies (REMS) for post-marketing safety monitoring
Regulatory inspections and compliance requirements

The Impact of Generic Drugs

The entry of generic drugs into the market has far-reaching implications for both healthcare accessibility and affordability. Generic drugs offer cost-effective alternatives to branded drugs, promoting affordability and accessibility for the public at large. However, the market competition caused by generic entry also poses challenges for innovator companies, as they must strategize to maintain market share and recoup their research and development costs. Therefore, it becomes pertinent to strike a right balance between fostering innovation on one hand and enabling affordable healthcare alternatives on the other hand.

Position of patent linkage in India

The patent linkage system is not prevalent in India as it is not backed by legislation as seen in the Hatch-Waxman Act of the USA. The debate as to the existence of patent linkage system in India sparked with the case of Bristol Myers Squibb Company v. Hetero Drugs. The court in this case ruled that the DCGI while exercising their statutory function must ensure that the marketing approval thus provided does not violate any valid patents. This imposes an additional burden on the drug regulatory authority which sparked the debate as the same is not backed by any legislation. This issue was put to rest with the case of Bayer Corporation v. Cipla and Union of India in which the judiciary affirmed that the patent linkage system does not exist in India and creating an additional burden for the drug regulatory authority affects the independence of both the systems.

Conclusion

The interwoven realms of patent linkage, generic drug entry, and regulatory approval processes demand a comprehensive understanding from all industry players. By navigating these complexities with strategic acumen, innovator companies can protect their investments while generic manufacturers can seize market opportunities. Ultimately, the overarching goal remains to promote innovation while ensuring access to affordable healthcare solutions for patients worldwide. By embracing a collaborative approach and fostering open dialogue among stakeholders the industry can collectively navigate these intricate waters, paving the way for a future where innovation and accessibility coexist harmoniously.

References

https://indiankanoon.org/doc/1123372/